glp 1 and crohn's disease Pharmacological interventions for obesity in patients with inflammatory bowel disease: A systematic review of GLP-1 receptor agonist efficacy safety GLP-1 Agonists and Crohn's Disease:
Description
Women benefit most when we treat menopause as the metabolic inflection point it isnot just prescribing GLP-1s in isolation, but considering hormone therapy, addressing sleep disruption (which drives cortisol and undermines any weight loss effort), and building strength to counter the lean mass loss these medications can cause
Heart failure with preserved ejection fraction (HFpEF) is the most common form of HF, especially among people with obesity
Exploring the link between semaglutide and fertility
Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a groundbreaking treatment for Type 2 diabetes mellitus (T2DM) and obesity
